Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.

• Main Authors: Thi Huyen Tram Nguyen (Author), Jérémie Guedj (Author), Xavier Anglaret (Author), Cédric Laouénan (Author), Vincent Madelain (Author), Anne-Marie Taburet (Author), Sylvain Baize (Author), Daouda Sissoko (Author), Boris Pastorino (Author), Anne Rodallec (Author), Géraldine Piorkowski (Author), Sara Carazo (Author), Mamoudou N Conde (Author), Jean-Luc Gala (Author), Joseph Akoi Bore (Author), Caroline Carbonnelle (Author), Frédéric Jacquot (Author), Hervé Raoul (Author), Denis Malvy (Author), Xavier de Lamballerie (Author), France Mentré (Author), JIKI study group (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2017-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BACKGROUND:In 2014-2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy agains...